/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. BiotechTV - News
  2. HCW 2026: Innate Pharma announced a deal with Sobi last month that will move lacutamab towards a registration filing - their partner Astra also has a huge readout coming soon for monalizumab
HCW 2026: Innate Pharma announced a deal with Sobi last month that will move lacutamab towards a registration filing - their partner Astra also has a huge readout coming soon for monalizumab

HCW 2026: Innate Pharma announced a deal with Sobi last month that will move lacutamab towards a registration filing - their partner Astra also has a huge readout coming soon for monalizumab

BiotechTV - News · Sep 14, 2026

Innate Pharma secures a key deal with Sobi for lacutamab, anticipates a major readout for monalizumab, and advances a differentiated ADC.

AstraZeneca Partnership Could Provide $825M in Non-Dilutive Funding for Innate's Next Pipeline

Success in the monalizumab trial with AstraZeneca would trigger up to $825 million in milestones. Innate's CEO explicitly frames this potential windfall as the key source of non-dilutive funding to finance the company's next generation of antibody-drug conjugate (ADC) programs.

HCW 2026: Innate Pharma announced a deal with Sobi last month that will move lacutamab towards a registration filing - their partner Astra also has a huge readout coming soon for monalizumab thumbnail

HCW 2026: Innate Pharma announced a deal with Sobi last month that will move lacutamab towards a registration filing - their partner Astra also has a huge readout coming soon for monalizumab

BiotechTV - News·2 months ago

Innate Pharma's ADC Strategy Targets the Weaknesses of an Approved Competitor Drug

Innate is developing its Nectin-4 ADC by directly addressing the shortcomings of the approved competitor, PADCEF. Their strategy involves a different drug payload to overcome resistance, a binder that targets more tumor types, and a proprietary linker to improve the safety profile, creating a 'better follower' product.

HCW 2026: Innate Pharma announced a deal with Sobi last month that will move lacutamab towards a registration filing - their partner Astra also has a huge readout coming soon for monalizumab thumbnail

HCW 2026: Innate Pharma announced a deal with Sobi last month that will move lacutamab towards a registration filing - their partner Astra also has a huge readout coming soon for monalizumab

BiotechTV - News·2 months ago

Innate Pharma's Sobi Deal Unlocks Accelerated FDA Approval Using Existing Phase 2 Data

The partnership with Sobi provides capital to initiate a required Phase 3 trial. Starting this trial allows Innate Pharma to immediately file for accelerated FDA approval for lacutamab based on their existing, positive Phase 2 data, creating a faster path to market.

HCW 2026: Innate Pharma announced a deal with Sobi last month that will move lacutamab towards a registration filing - their partner Astra also has a huge readout coming soon for monalizumab thumbnail

HCW 2026: Innate Pharma announced a deal with Sobi last month that will move lacutamab towards a registration filing - their partner Astra also has a huge readout coming soon for monalizumab

BiotechTV - News·2 months ago